Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BLUE crawled time : 13:00 save search
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
Published: 2023-08-16 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: -1.66%
H: 2.81%
C: 0.28%
fda disease cell meeting therapy
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
Published: 2023-08-08 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: -1.94%
H: 24.08%
C: 10.2%
financial results
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
Published: 2023-07-25 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 0.0%
H: 6.77%
C: -1.82%
conference update commercial financial results
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
Published: 2023-01-18 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: -9.07%
H: 4.98%
C: -8.99%
offering
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 0.0%
H: 1.23%
C: -6.75%
fda disease clinical hold
bluebird bio Announced September Investor Events
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
MS | News 0 d | $92.09 1.58% 0.12% 2.9K
|
Finance
|
| O: -0.77%
H: 0.34%
C: -0.92%
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: -1.35%
H: 5.81%
C: 0.85%
BioSpace Movers & Shakers, April 15: Spruce, Nautilus, Alto, Ikena Oncology
Published: 2022-04-15 (Crawled : 13:00) - biospace.com/
MSFT | News F | $400.96 0.46% 0.43% 140K
|
Technology Services
| Email alert
Add to watchlist
BSX | $68.02 1.03% 0.29% 6.5M
|
Health Technology
| Email alert
Add to watchlist
AUTL | $4.56 0.89% 1.31% 1.1M
|
Health Technology
| Email alert
Add to watchlist
EXEL | $22.87 1.55% 1.49% 1.5M
|
Health Technology
| Email alert
Add to watchlist
MRNA | News S | $104.46 3.01% 2.94% 2.1K
|
Health Technology
| Email alert
Add to watchlist
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
AVRO | $1.2 0.41% 0
|
Health Technology
| Email alert
Add to watchlist
MACK 4 | $14.73 0.07% 0.2% 95K
|
Health Technology
| Email alert
Add to watchlist
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.07 -0.2% 0.18% 3.8M
|
Health Technology
| Email alert
Add to watchlist
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-11 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: 0.0%
milestone
2seventy bio Announces Upcoming Investor Events
Published: 2021-09-13 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 0.06%
H: 4.08%
C: 2.24%
bluebird bio Secures $75 Million in Private Placement Equity Financing
Published: 2021-09-08 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 0.63%
H: 3.55%
C: 2.23%
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
Published: 2021-07-09 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 0.0%
H: 2.73%
C: 0.46%
gene therapy positive therapy gene therapies
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 4.85%
H: 0.46%
C: -1.36%
disease fda clinical hold
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
Published: 2021-05-21 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 0.98%
H: 2.74%
C: 1.71%
gene therapy positive therapy gene therapies chmp
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
Published: 2021-05-13 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 0.5%
H: 1.6%
C: -2.3%
disease genetic
bluebird bio Announces May Investor Events
Published: 2021-05-03 (Crawled : 13:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K
|
Health Technology
|
| O: 0.57%
H: 0.99%
C: -1.89%
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M
|
Finance
EDBL | News | $6.26 66.49% 48.56% 270K
|
MLEC | $2.47 76.43% 38.05% 460K
|
n/a
PEGY | $0.0458 -10.2% 28.77% 79M
|
Manufacturing
PALI | $4.93 4.67% 25.83% 2.1M
|
Manufacturing
SILO | $1.99 0.71% 20.64% 1.8M
|
Finance and Insurance
NNVC | $1.12 1.82% 19.64% 2.5K
|
Health Technology
CANG | $1.34 -4.29% 14.93% 120K
|
Technology Services
AZTR 4 | $0.195 13.85% 42K
|
n/a
TOVX | News | $0.411 -1.01% 12.9% 230K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.